OHSU takes public stance against calls to close primate research center
PORTLAND, Ore. () — Oregon Health and Science University has publicly sounded off against the push for the institution to close its monkey research facility.
On Wednesday, the university published an announcement addressing animal advocates' claims on why the Oregon National Primate Research Center should be shut down.
'Usually somebody blabs': Tony White's 2005 death still unsolved
People for the Ethical Treatment of Animals, better known as PETA, asked the National Institutes for Health's Office of Laboratory Animal Welfare to investigate the OHSU center in mid-April. The organization's revealed a 4-year-old monkey died a 'painful death' from sepsis last year after people at the Beaverton facility ignored her symptoms.
The Physicians Committee for Responsible Medicine has also slammed the research center, referring to it as a the university could replace by further investing in patient care.
In response, OHSU said the claim 'compares apples to oranges.' The institution noted the facility is mostly funded by federal grants that only cover specific research efforts, which improve patient care by identifying new ways to treat diseases.
The university also pushed back on animal advocates' argument that the research is cruel and unnecessary.
'While scientific advancements have introduced alternative non-animal models, this technology cannot fully replicate the complexity of a living system at this time,' OHSU . 'Nonhuman primate research remains critical for studying conditions such as Alzheimer's, Parkinson's, infectious diseases and reproductive health — areas where animal-free methods cannot yet provide complete answers.'
May Day rally in Salem defends immigrant workers' rights, opposes sanctuary city cuts
The institution noted that animal research is heavily regulated by federal authorities. OHSU also claimed its primates grow up with their social groups and form bonds with researchers in the facility.
Many of the university's points were shared in the rally that researchers held on the west campus last month, after Oregon Gov. Tina Kotek urged leaders to close the primate facility.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
5 hours ago
- New York Post
Powerful pill can reveal what's going on in your gut — thanks to miniature sensors
Time to swallow your feelings. It's no secret that gut health is being treated like the ultimate biohack these days, as ongoing research shows your digestive system impacts your skin, immune system, energy levels and even your mood. Studies have even found links between the gut and Parkinson's, colon cancer and other conditions, with doctors routinely recommending people get more fiber in their diets. Researchers at Caltech have developed a capsule that can measure your gut health. T Mdlungu/ – So it might be no surprise that the geniuses over at Caltech have invented a tiny pill called PillTrek that's lined with electrochemical sensors that measure pH, temperature, metabolites, ions — even serotonin and dopamine — right in your gut. The pill is itty-bitty — measuring 7 millimeters in diameter and 25 millimeters in length — but it packs a powerful punch. 'We designed this pill to be a very versatile platform,' Wei Gao, a professor of medical engineering at Caltech and a Heritage Medical Research Institute Investigator, said in a press release. 'From an electrochemical-sensing point of view, it is very powerful. It has the ability to measure metabolites, ions, hormones such as serotonin and dopamine, possibly even proteins as well. And all within the gut, which is a complex environment.' The PillTrek smart capsule measures just 7 millimeters in diameter and 25 millimeters in length. Jihong Min and Wei Gao Current gut tests rely on messy stool samples or pricey, invasive biopsies — and offer only snapshot insights. Conversely, this smart capsule offers a window into a future where assessing your gut health — which is also a marker of overall health and a good way of detecting diseases early — can be relatively easy. 'Ingestible capsules have significant potential in diagnosis, monitoring and management of chronic conditions, but previous devices were very limited in terms of their sensing capabilities, lifetime, and size,' said Azita Emami, who is working with Gao to make the pill even smaller and more energy-efficient. 'This work is an important translational step toward devices that can provide meaningful medical information for patients and physicians.' Researchers outlined the pill in a paper published in the journal Nature.
Newsweek
a day ago
- Newsweek
This New Test Could Diagnose Parkinson's With AI
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new artificial intelligence (AI) tool analyzing short smile videos achieved high accuracy in screening for Parkinson's disease (PD), according to research published by Tariq Adnan, and colleagues in the New England Journal of Medicine (NEJM) Thursday. The model was trained on the largest known video dataset of facial expressions to date, enrolling 1,452 participants, including 391 living with PD. An 87.9 percent overall accuracy in detecting PD using only smile video analysis, the NEJM AI study reported. Researchers reported that the AI model could accurately distinguish between individuals with and without PD based on the analysis of their smiles, even when applied in diverse population samples from North America and Bangladesh. Why It Matters The Parkinson's Foundation says an estimated 90,000 more people will be diagnosed this year, with the number of those suffering expected to be around 1.2 million by 2030. Diagnosing Parkinson's disease early remains a significant challenge because of limited access to clinical expertise and in-person evaluations. AI-driven remote screening tools promise scalable, cost-effective solutions to bridge these healthcare gaps. The findings align with the growing demand for digital healthcare solutions that remove geographical and economic barriers to early neurological disease diagnosis, which is especially relevant to rural and underserved American communities. What To Know The new screening method invited participants to record themselves mimicking facial expressions—including a smile—using an online platform. Research teams then extracted facial landmarks and measured action units to quantify hypomimia, a common motor symptom in PD where facial muscle movement is diminished. Machine learning models were developed using these features, distinguishing people with PD from those without. The approach relied on a broad recruitment strategy, involving participants from North America via social media, email, wellness centers, and research registries, alongside a high-risk cohort from Bangladesh. Trained solely on smile videos, the model achieved a 10-fold cross-validated accuracy of 87.9 percent, a sensitivity of 76.8 percent, and a specificity of 91.4 percent. Validation in external test sets revealed 80.3 percent accuracy in a U.S. clinic dataset and 85.3 percent accuracy in the Bangladesh cohort. While the negative predictive value remained above 92 percent in all settings, the positive predictive value dropped to 35.7 percent among the Bangladeshi participants, reflecting variations in population characteristics. The study found no significant differences in model performance across sex and ethnic subgroups, except for marginally higher accuracy in female participants in Bangladesh. The authors emphasized the generalizability and fairness of the approach, key considerations in the development of clinical AI tools. The video-processing and machine-learning code supporting the study is available to the public on GitHub. However, the study authors noted that raw video data sharing is restricted to comply with U.S. healthcare privacy law (HIPAA), limiting access to de-identified derivative features only. The research received funding from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, among other sources. The work was a collaborative effort involving academic and clinical partners such as the InMotion Parkinson's Disease wellness center and the University of Rochester Center for Health and Technology. The research process also benefited from contributions by staff at Google Research and the University of Rochester, particularly in statistical analysis. Stock image of brain MRI taken November 21, 2018. Stock image of brain MRI taken November 21, 2018. Getty What People Are Saying Tariq Adnan, lead author said in the study conclusion: "Smiling videos can effectively differentiate between individuals with and without PD, offering a potentially easy, accessible, and cost-efficient way to screen for PD, especially when access to clinical diagnosis is limited." What Happens Next? Future steps for the research team involve wider validation of the AI screening method in additional, real-world populations and further refinement of the algorithm to maximize early detection accuracy. Regulatory and clinical translation pathways will determine if and when this technology becomes available in the United States healthcare system.
New York Post
a day ago
- New York Post
This common kitchen herb ingredient could help target or slow Alzheimer's
Experts believe they've identified a chemical compound in certain herbs that could help mitigate or prevent Alzheimer's disease — but before anyone makes a run for the spice rack, there are a few catches. In a study published in the journal Antioxidants earlier this year, researchers from the Scripps Research Institute identified a compound called carnosic acid, which is prevalent in rosemary and sage. Advertisement The compound could prove therapeutic for neurodegenerative disorders, including Alzheimer's disease, the experts concluded. Carnosic acid contains 'striking antioxidant [and] anti-inflammatory properties,' the researchers wrote in the findings. Scripps Research postdoctoral associate Piu Banerjee and board-certified neurologist Dr. Stuart Lipton, based in California, spoke with Fox News Digital about the results. 'In this study, we observed that administering this drug to mice that had advanced Alzheimer's-like disease significantly improved the number of neurons, as well as the number of synapses or connections between the brain cells,' the team said. Advertisement 4 Experts believe they've identified a chemical compound, carnosic acid, in certain herbs like rosemary and sage that could help mitigate or prevent Alzheimer's disease. Brent Hofacker – The experts added, 'It also reduced inflammation that is caused by the current anti-amyloid antibody therapies. We also observed an improvement in the learning and memory behavior of the mice that received the drug.' Banerjee and Lipton also noted that carnosic acid is a 'prodrug,' meaning it's inactive at first — but once it enters the body, it's activated by oxidative and inflammatory stress. 'It specifically targets cells undergoing oxidative and inflammatory stress, without affecting the healthy, normal brain cells,' Banerjee said. Advertisement 'This further makes it a safe option for therapeutics.' The experts agreed that carnosic acid could potentially improve the inflammation that generally occurs in most aging brains. There are cautions, however. Advertisement Courtney Kloske, director of scientific engagement for the Chicago-based Alzheimer's Association, told Fox News Digital that studies based on a mouse model of Alzheimer's can be helpful but are not conclusive. 4 Experts say carnosic acid could improve inflammation occurring in most aging brains. LIGHTFIELD STUDIOS – 'Models are important in helping us understand the basic biology of the disease, but we need human studies in representative populations for ideas to be fully validated,' Kloske said. 'Therefore, while these are intriguing findings, more research is needed to understand the impacts and outcomes of these compounds on people living with, or at risk for, Alzheimer's.' Cooking sage and rosemary won't provide the full anti-inflammatory effects, Banerjee and Lipton stressed. 4 'We need human studies in representative populations for ideas to be fully validated,' Courtney Kloske, director of scientific engagement for the Chicago-based Alzheimer's Association, says about the limitations of the information. – 'Critically, one cannot take sufficient herbs safely to produce the same effect as our new drug,' Banerjee said. The study, funded in part by the National Institutes of Health, did have some limitations, the researchers acknowledged. Advertisement Kloske advised that, at this point, 'no one should consume these herbs (or carnosic acid) to prevent or treat Alzheimer's or other cognitive impairment.' 4 According to Scripps Research postdoctoral associate Piu Banerjee and board-certified neurologist Dr. Stuart Lipton, cooking sage and rosemary won't provide the full anti-inflammatory effects. Ganna – Dr. Lee Murray, a neurologist in Jackson, Tennessee, echoed Kloske's concerns. 'Before patients start incorporating rosemary and sage in every dish they eat, we need to remember these studies are pre-clinical,' Murray told Fox News Digital. Advertisement 'Currently, there is insufficient clinical evidence to recommend rosemary and sage as a standard therapy for Alzheimer's dementia.' Murray, however, said the data 'is encouraging' and opens the door to additional pathways for potential therapeutics. Banerjee said she hopes that 'our drug will start human clinical trials soon.' She added, 'If it proves to be effective, it will be a great new drug for those suffering from Alzheimer's … From the results of our animal studies, we are cautiously optimistic for its success in human clinical trials.'
